Abstract

Present at the Midyear Clinical Meeting.

This evaluation found that most vaccinated patients met criteria. About 1/3 of newborns received RSV protection, but post-birth nirsevimab use could not be confirmed for non-Parkview patients.

Document Type

Poster

Publication Date

2025

Share

COinS